Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting
January 25 2022 - 7:30AM
Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company
dedicated to the development of innovative therapeutics for
neurotology, today announced multiple presentations at the upcoming
Association for Research in Otolaryngology (ARO) 45th Annual
MidWinter Meeting, to be held virtually during February.
Otonomy is participating in a workshop entitled “Translational
delivery approaches for inner ear therapies” that will be held from
11 a.m. to 1 p.m. ET on February 11. The Otonomy presentation topic
and presenter are as follows:
- “Factors in intratympanic drug delivery for the inner ear” by
Bonnie Jacques, Ph.D.
All other presentations are posters that will be available for
registered attendees via the conference website beginning on
February 1.
Poster presentations by Otonomy authors:
- “OTO-825 gene therapy rescues hearing loss and cochlear
degeneration in a clinically relevant inducible mouse model of GJB2
congenital hearing loss” by Mathur et al. (poster #323)
- “AAV-mediated gene therapy with OTO-825 rescues hearing loss
and cochlear degeneration in a clinically relevant tissue specific
mouse model of GJB2 congenital hearing loss” by Uribe et al.
(poster #330)
- “Identification and characterization of a novel therapeutic
class of otoprotectants for the prevention of cisplatin-induced
hearing loss”, poster by Fernandez et al. (poster #527)
Poster presentations by Otonomy collaborators:
- “The Trkb-selective agonist monoclonal antibody M3 promotes in
vivo spiral ganglion cell survival in deafened guinea pigs” by Vink
et al. (poster #514)
- “Development of an enhanced screening assay to distinguish
between hair cell regeneration and otoprotection” by Singh et al.
(poster #751)
About Otonomy
Otonomy is a biopharmaceutical company dedicated to the
development of innovative therapeutics for neurotology. The company
pioneered the application of drug delivery technology to the ear in
order to develop products that achieve sustained drug exposure from
a single local administration. This approach is covered by a broad
patent estate and is being utilized to develop a pipeline of
products addressing important unmet medical needs with a focus on
hearing loss and tinnitus. For additional information please visit
www.otonomy.com.
Contacts:
Media Inquiries:Spectrum ScienceChloé-Anne RamseyVice
President404.865.3601cramsey@spectrumscience.com
Investor Inquiries:Westwicke ICRRobert H. UhlManaging
Director858.356.5932robert.uhl@westwicke.com
Otonomy (NASDAQ:OTIC)
Historical Stock Chart
From May 2024 to Jun 2024
Otonomy (NASDAQ:OTIC)
Historical Stock Chart
From Jun 2023 to Jun 2024